Smoking and schizophrenia
| Autor: | Joseph P. McEvoy, John C. Lindgren |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Psychosis
education.field_of_study medicine.medical_specialty Sensory gating medicine.drug_class business.industry medicine.medical_treatment Population Atypical antipsychotic medicine.disease Nicotine medicine.anatomical_structure Schizophrenia Internal medicine mental disorders Drug Discovery medicine education business Antipsychotic Psychiatry Clozapine medicine.drug |
| Zdroj: | Drug Development Research. 38:263-266 |
| ISSN: | 1098-2299 0272-4391 |
| Popis: | Patients with schizophrenia smoke at a higher prevalence rate (80%) than the general population (30%). Those patients with schizophrenia who smoke have an earlier age of onset and may have more refractory psychopathology. Smoking improves sensory gating, sustained attention, and cognitive performance in patients with schizophrenia. Conventional antipsychotic drugs initially increase smoking. Switching to the atypical antipsychotic, clozapine, decreases smoking. Smoking decreases the bioavailability of many antipsychotic drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text